Speaker Profile

M.D., M.P.H., Professor, UCSF

Biography
Dr. Burchard is a Latino physician-scientist. He initiated and now directs the largest study of asthma in minority children in the U.S. and is currently the lead PI involving a birth cohort of minority children in Puerto Rico. Dr. Burchard is the Director of the UCSF Asthma Collaboratory, a large interdisciplinary research program focusing on minority children and gene-environment interactions for asthma. Dr. Burchard’s team was the first to leverage genetic ancestry to identify novel genetic and environmental risk factors for lung disease and poor drug response among minority children with asthma. Dr. Burchard earned his MD from Stanford University School of Medicine, completed residency at the Brigham and Women's Hospital, MA and a fellowship at the University of California, San Francisco. Dr. Burchard has formal training and expertise in internal medicine, pulmonary and critical care medicine, epidemiology, molecular genetics, genetic and clinical research.

Talk
Making Precision Medicine Socially Precise
How minority children with severe asthma do not qualify for modern asthma biologic drugs because of racial variation in targeted biomarkers


 Session Abstract – PMWC 2022 Silicon Valley


Track Chairs:
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford

Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.

  • Keynote: The Future Of PGx
    - Julie Johnson, University of Florida
  • PGx Research and Discovery
    - Estenab Burchard, UCSF
    - William Evans, St. Jude's
    - Jose Estabil, Cipherome
    - James Coons, UPMC
    - Todd Skaar, Indiana University
  • Innovative Industry Solutions
    - Jeffrey A. Shaman, Coriell Life Sciences
    - Akwasi Asabere, Helix
    - Gillian Bell, Genome Medical
    - Cindy Kosinski, 23andme
  • Key Resources for PGx
    - Kelly E. Caudle, St. Jude Children’s Research Hospital
    - Michelle Whirl-Carillo, Stanford
  • Clinical Laboratory PGx Considerations
    - Ulrich Broeckel, MCW
    - Stuart Scott, Stanford
    - Victoria Pratt, Indiana University
  • Lessons from Frontline PGx Clinical Services
    - Mark H. Dunnenberger, Northshore University HealthSystem
    - Lucas Berenbrok, UPitt
    - Sony Tuteja, UPenn
    - Burns Blaxall, The Christ Hospital Health Network
  • Translational PGx Implementation Programs
    - Philip Empey, UPitt
    - Julie A. Johnson, Uinversity of Florida
    - Mary V. Relling, St. Jude Children’s Research Hospital
    - Laura Ramsey, Cincinnati Children's Hospital
    - Nita A. Limdi, UAB